BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 118 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.75 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $51,242 | -26.5% | 10,087 | -13.3% | 0.00% | -33.3% |
| Q4 2023 | $69,676 | -15.4% | 11,632 | 0.0% | 0.00% | -25.0% |
| Q3 2023 | $82,355 | +16.7% | 11,632 | +16.0% | 0.00% | +33.3% |
| Q2 2023 | $70,597 | -15.6% | 10,028 | 0.0% | 0.00% | -25.0% |
| Q1 2023 | $83,634 | -36.5% | 10,028 | -12.5% | 0.00% | -33.3% |
| Q4 2022 | $131,630 | -5.9% | 11,466 | +3.3% | 0.01% | -14.3% |
| Q3 2022 | $139,885 | +19.1% | 11,102 | 0.0% | 0.01% | +40.0% |
| Q2 2022 | $117,459 | -34.9% | 11,102 | 0.0% | 0.01% | -16.7% |
| Q1 2022 | $180,519 | -72.5% | 11,102 | -76.6% | 0.01% | -33.3% |
| Q4 2021 | $656,047 | -3.6% | 47,368 | 0.0% | 0.01% | -10.0% |
| Q3 2021 | $680,678 | -17.3% | 47,368 | -9.0% | 0.01% | -16.7% |
| Q2 2021 | $823,290 | +68.7% | 52,074 | +8.5% | 0.01% | +71.4% |
| Q1 2021 | $488,007 | +27.3% | 47,985 | -6.8% | 0.01% | +16.7% |
| Q4 2020 | $383,444 | +107.5% | 51,469 | -4.3% | 0.01% | +100.0% |
| Q3 2020 | $184,782 | -23.5% | 53,794 | +6.1% | 0.00% | -25.0% |
| Q2 2020 | $241,533 | +138.2% | 50,689 | -0.0% | 0.00% | +100.0% |
| Q1 2020 | $101,380 | -41.7% | 50,690 | +0.6% | 0.00% | -33.3% |
| Q4 2019 | $173,801 | +64.1% | 50,377 | +36.3% | 0.00% | +50.0% |
| Q3 2019 | $105,922 | -24.4% | 36,971 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $140,120 | -53.4% | 36,971 | 0.0% | 0.00% | -60.0% |
| Q1 2019 | $300,944 | +0.9% | 36,971 | 0.0% | 0.01% | -16.7% |
| Q4 2018 | $298,356 | +8.9% | 36,971 | +3.0% | 0.01% | +20.0% |
| Q3 2018 | $273,948 | -99.8% | 35,904 | +14.7% | 0.01% | +66.7% |
| Q2 2018 | $179,429,000 | +20.1% | 31,314 | 0.0% | 0.00% | +50.0% |
| Q1 2018 | $149,368,000 | +113057.6% | 31,314 | +16.7% | 0.00% | 0.0% |
| Q4 2017 | $132,000 | -58.1% | 26,823 | -55.4% | 0.00% | 0.0% |
| Q3 2017 | $315,000 | -5.7% | 60,076 | -0.1% | 0.00% | 0.0% |
| Q2 2017 | $334,000 | -33.9% | 60,126 | 0.0% | 0.00% | -50.0% |
| Q1 2017 | $505,000 | +40.7% | 60,126 | +5.9% | 0.00% | +33.3% |
| Q4 2016 | $359,000 | +33.0% | 56,787 | -7.2% | 0.00% | +50.0% |
| Q3 2016 | $270,000 | +50.0% | 61,186 | -3.7% | 0.00% | +100.0% |
| Q2 2016 | $180,000 | -66.6% | 63,516 | +21.7% | 0.00% | -75.0% |
| Q4 2015 | $539,000 | -9.4% | 52,196 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $595,000 | -23.6% | 52,196 | 0.0% | 0.00% | -20.0% |
| Q2 2015 | $779,000 | +17.1% | 52,196 | -4.6% | 0.01% | 0.0% |
| Q4 2014 | $665,000 | +24.3% | 54,718 | 0.0% | 0.01% | +25.0% |
| Q3 2014 | $535,000 | -23.4% | 54,718 | 0.0% | 0.00% | -20.0% |
| Q2 2014 | $698,000 | – | 54,718 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
| Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
| Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
| Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
| ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
| TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
| MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
| Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
| Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
| Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |